Ethris GmbH was founded in 2009 and started its research activities in January 2012. The company specializes in developing mRNA medicines for prevention and treatment of lung diseases and in 2024 focused on programs ETH47 (nasal mRNA IFNλ product in lipidoid nanoparticles, Phase I study with database closure in August 2024) and ETH42 (mRNA therapy for primary ciliary dyskinesia, first GMP production in 2024). Ethris holds a patent portfolio across 31 patent families with more than 360 granted patents and over 114 pending patents. Financing in 2024 came from public grants (approx. EUR 3.3m), R&D contracts (more than EUR 3m with Cipla and Heqet) and convertible loans; revenues were EUR 3,119,610.26 and the average number of employees was 59.
Erforschung und Entwicklung von neuen Therapieverfahren und -produkten zur Behandlung erworbener und angeborener Erkrankungen sowie im Zusammenhang damit der Erwerb und die Vergabe von Lizenzen und Übernahme von Beratungs-, Handels- und Vertriebsaktivitäten.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 182200 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Christian Plank | Geschäftsführer(in) | Weßling |
| Carsten Rudolph | Geschäftsführer(in) | Krailling |
| Christian Wawrzinek | Geschäftsführer(in) | Hamburg |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 182200 (as of 1 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 19.02.2026 | Registered Seat Change | Planegg, Landkreis München |
| 19.02.2026 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 10.06.2024 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 19.02.2026 | Capital Increase | +2.782 € | 98.856 € |
| 11.01.2023 | Capital Increase | +9.939 € | 96.074 € |
| 16.02.2022 | Capital Increase | +23.169 € | 86.135 € |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 182200 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €3,119,610 | -€9,318,243 | €12,638,099 | — |
| 2023 | €171,583 | -€14,521,579 | €16,735,180 | — |
| 2022 | ≤ €12M1 | -€9,347,561 | €14,982,941 | — |
| 2021 | small company1 | €273,735 | €5,230,196 | — |
| 2020 | small company1 | €3,793,155 | €4,488,682 | — |
| 2019 | ≤ €12M1 | -€2,235,279 | €13,854,807 | — |
| 2018 | ≤ €12M1 | -€47,227 | €18,791,114 | — |
| 2017 | ≤ €12M1 | -€3,201,217 | €23,832,783 | — |
| 2016 | small company1 | -€5,769,643 | €3,195,665 | — |
| 2015 | ≤ €12M1 | -€3,915,150 | €7,413,353 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 182200 (as of 1 November 2026)
Reaction Biology Europe GmbH
Freiburg im Breisgau · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
CLIMATE ANALYTICS gGmbH
Berlin · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
IMMS Institut für Mikroelektronik- und Mechatronik-Systeme gemeinnützige GmbH (IMMS GmbH)
Ilmenau · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
| Cost type | Amount | Share |
|---|---|---|
| Interest & Similar | €270,316 | 100.0% |
